FDA action or review extension for Capricor's Deramiocel is due after a 3 to 9 negative panel vote

Quick Trade Summary: Upcoming catalyst FDA action on Deramiocel is targeted for August 22, 2026. Capricor plans to amend the application with longer-term data and a revised focus on upper limb function. The FDA could extend the review instead of issuing a final approval decision. I cannot confirm that the FDA has accepted this amendment. Main stock affected Capricor Therapeutics, Nasdaq ticker CAPR. Current price and time $6.39 at 2026-08-21 16:34:16 UTC. Regular US market session. Expected stock reaction Mixed, with negative skew. A review extension may produce a small gain or little reaction because extension expectations are partly priced in. A rejection could cause a sharp decline. Surprise approval could more than double the stock. Action before the event Avoid a pre-event position. This is a high-risk binary setup after a negative FDA panel vote. The preferred trade is after the announcement. If the FDA accepts the amendment, extends the review and does not demand another pivotal trial, watch for CAPR to hold above $7.00 for at least 30 minutes. A possible trading plan is entry above $7.00, risk below $6.00 and an initial target of $8.00 to $9.00. Do not chase an opening spike. Why the stock is affected Deramiocel is Capricor's only late-stage product and the company currently has no product revenue. Approval would change CAPR from a development company into a commercial biotechnology company. It could also make Capricor eligible for a transferable Priority Review Voucher. A rejection would delay revenue, increase development costs and extend the period of cash burn. The company has also paused or slowed other programs while waiting for regulatory clarity. This makes the FDA outcome central to almost the entire valuation. Catalyst confidence The event date is confirmed as the published FDA target date. My base forecast is a review extension after submission of the planned amendment, rather than immediate approval. Forecast probability is about 60%. I assign about a 30% probability to a Complete Response Letter or another negative regulatory action and about a 10% probability to surprise approval. These are trading estimates, not published FDA probabilities. Stock-reaction confidence High confidence that CAPR will move sharply if the FDA approves or rejects the application. Medium confidence in the direction because an extension can be interpreted in two ways. It avoids immediate rejection, but it also delays revenue and may require more evidence. Detailed Analysis: When the market will react August 22, 2026 is a Saturday. If the FDA announces on Friday, August 21, the first reaction could occur during regular trading or after hours. If news arrives during the weekend, the main reaction should begin at the Nasdaq open on Monday, August 24, 2026, at 13:30 UTC. The most important trading window is the first 30 minutes through the first two sessions. Approval or rejection could affect the valuation for months. Effect on the business Approval would create CAPR's first commercial product and could unlock product revenue, launch spending and a Priority Review Voucher. It would also strengthen the value of Deramiocel in Europe, Japan and possible additional muscular dystrophy indications. An extension would preserve the approval path but delay revenue. Capricor reported no revenue for the first half of 2026, $42.9 million of second-quarter operating expenses and a $40.7 million quarterly net loss. A rejection could require another study. That would increase cash burn and delay commercialization. The company held about $237.9 million in cash, cash equivalents and marketable securities on June 30, 2026. Market expectations and forecast There is no verified public consensus probability for the FDA outcome. Price action shows that traders expect an extension to be possible, but do not fully price in approval. My forecast is: Extension, 60% probability. Expected reaction from about negative 10% to positive 20%. Negative action, 30% probability. Expected reaction from negative 35% to negative 55%. Approval, 10% probability. Expected reaction from positive 100% to positive 200%. The extension needs clear language that the FDA will review the new data without requiring a new pivotal trial. Without that language, an initial gain may fade. Recent price action and priced-in level Priced-in level is medium. CAPR closed at $19.70 on July 24, before FDA briefing documents damaged confidence. At $6.39, the stock is down 67.6% from that level. Calculation: $6.39 divided by $19.70, minus 1, equals negative 67.6%. The stock closed at $4.21 on August 13, then rose 58.0% to $6.65 on August 14 after the regulatory update. August 14 volume reached 66.3 million shares, compared with roughly 1 million to 4 million shares on many normal sessions before the FDA controversy. At $6.39, CAPR remains 51.8% above the August 13 close. Calculation: $6.39 divided by $4.21, minus 1, equals 51.8%. This shows that part of the extension scenario is already priced in. I cannot confirm a matching sector-wide move in DMD peers. Treat the recent volatility as mainly company-specific. Expected price move and duration Impact rating is High. A normal extension announcement could move the stock 10% to 25% in either direction. A rejection could produce a 35% to 55% decline. Surprise approval could produce a gain above 100%, because the stock traded near $20 before the FDA briefing documents and panel vote. The largest move should occur over one or two sessions. An extension-related move may fade within a week. Approval or a demand for a new trial could reset the valuation for several months. Result needed for a big move For a large positive move, the FDA must approve Deramiocel or accept the amendment while clearly indicating that another pivotal trial is not required. A simple extension without details is unlikely to support a lasting move above 20%, because traders already expect an extension to be possible. A Complete Response Letter requiring a new controlled trial would likely create the largest negative move. Possible outcomes Positive scenario The FDA approves Deramiocel, possibly with a narrower upper limb function label. Expected stock reaction is positive 100% to 200%. A clean amendment acceptance without a new trial requirement could instead produce a 20% to 50% gain. Neutral scenario The FDA extends the review but gives limited information about the approval standard or additional evidence required. Expected reaction is negative 10% to positive 15%, followed by volatile trading. Negative scenario The FDA rejects the application, refuses the amendment or requires another pivotal trial. Expected reaction is negative 35% to negative 55%. The stock could temporarily trade below the company's cash and securities per share because cash burn, liabilities and future trial costs reduce the value of that cash. Other affected stocks Sarepta Therapeutics, SRPT, is the largest listed DMD-focused commercial competitor. Dyne Therapeutics, DYN, Wave Life Sciences, WVE, Entrada Therapeutics, TRDA, PepGen, PEPG, and Solid Biosciences, SLDB, have competing or related muscular dystrophy programs. A CAPR approval could improve investor confidence in the DMD market but increase future competition. A rejection based on Capricor-specific statistics should have limited peer impact. A broader FDA concern about DMD endpoints could pressure other developers. No directly exposed US-listed manufacturing supplier has been confirmed. What the market may be missing The stock trades close to a balance-sheet reference level, but it is not a simple cash-floor trade. Cash and securities per share were about $4.09. Calculation: $237.9 million divided by 58.1 million shares equals about $4.09 per share. The current $6.39 price therefore assigns roughly $2.30 per share to Deramiocel, the pipeline and other net assets before accounting for future losses. The overlooked risk is that second-quarter operating expenses were $42.9 million. Continued spending can reduce the $4.09 cash reference quickly. The company also reported $122.5 million of total liabilities. The overlooked opportunity is a narrower upper limb label. The FDA panel voted against evidence for cardiomyopathy, but it did not vote on the HOPE-3 upper limb primary endpoint. HOPE-3 reported statistical significance on upper limb function at p=0.029. A narrower regulatory path could preserve substantial value even without the original cardiomyopathy claim. Main risks The FDA may reject the planned amendment or require another pivotal trial. The advisory committee voted 3 in favor and 9 against evidence of effectiveness for DMD cardiomyopathy. A corrected statistical analysis changed the left ventricular ejection fraction result from p=0.04 to p=0.09 in the full study population. An FDA inspection produced one Form 483 observation. Capricor submitted a response, but the final regulatory effect is not confirmed. The dispute with NS Pharma and Nippon Shinyaku could complicate pricing, distribution and launch timing. The FDA could announce after August 22 or set a new date outside this trading window. Other factors The scheduled action date falls on a weekend. Gaps at Monday's open could make stop orders execute far below their trigger prices. CAPR traded as low as $2.96 after the FDA controversy and as high as $8.29 on August 18. Position size matters more than a tight stop in this setup. The highest-priority trade is to preserve cash before the event, then trade the confirmed regulatory language. An extension alone is not enough. The key question is whether Capricor can pursue approval without funding and running another large controlled trial.